Clinical trial / 2017
High-dose vitamin B6 supplementation was linked to a 42% higher risk of hip fracture during extended follow-up, while folic acid plus B12 showed no effect.
Researchers analyzed combined data from two randomized controlled trials using a 2x2 factorial design to assess daily supplementation with folic acid (0.8 mg) plus B12 (0.4 mg), vitamin B6 (40 mg), both, or placebo on hip fracture risk. Folic acid plus B12 showed no significant association with hip fracture during the trial (HR 0.87; 95% CI, 0.48 to 1.59) or during extended follow-up (median 11.1 years; HR 1.08; 95% CI, 0.84 to 1.40). Vitamin B6 was not significantly associated with hip fracture during the trial (HR 1.42; 95% CI, 0.78 to 2.61), but was associated with a significant 42% higher risk during extended follow-up (HR 1.42; 95% CI, 1.09 to 1.83).
- Study type
- Secondary analysis of two 2x2 factorial randomized controlled trials
- Who was studied
- Participants from two large randomized controlled trials originally designed to study cardiovascular diseases
- What was measured
- Hip fracture risk during the trial and during extended follow-up (median 11.1 years)
THE PAPER
B Vitamins and Hip Fracture: Secondary Analyses and Extended Follow-Up of Two Large Randomized Controlled Trials.
Garcia Lopez M, Bønaa KH, Ebbing M, Eriksen EF, Gjesdal CG, Nygård O, Tell GS, Ueland PM, Meyer HE. J Bone Miner Res, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.